Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404687 | 1.00 | TAS1R3 (0.39) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL5399811 | 0.97 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL5399815 | 0.97 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL5402718 | 0.97 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL5406913 | 0.91 | TAS1R3 (0.42) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL5405651 | 0.79 | MEN1 (0.41) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL5405437 | 0.79 | MEN1 (0.38) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL5405439 | 0.79 | MEN1 (0.38) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL5413053 | 0.78 | MEN1 (0.40) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL5413891 | 0.78 | MEN1 (0.40) | TAS1R3TAS1R1TAS1R2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | claimed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | claimed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | claimed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | claimed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | claimed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | claimed |
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | TAS1R3 2481/4885TAS1R1 2567/4885TAS1R2 2841/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | TAS1R3 1612/4885TAS1R1 1996/4885TAS1R2 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.